Advertisement

 

 

Identification of a robust subpathway-based signature for acute myeloid leukemia prognosis using an miRNA integrated strategy.

Identification of a robust subpathway-based signature for acute myeloid leukemia prognosis using an miRNA integrated strategy.
Author Information (click to view)

Chang H, Gao Q, Ding W, Qing X,


Chang H, Gao Q, Ding W, Qing X, (click to view)

Chang H, Gao Q, Ding W, Qing X,

Advertisement

PloS one 2018 03 2313(3) e0194245 doi 10.1371/journal.pone.0194245
Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease, and survival signatures are urgently needed to better monitor treatment. MiRNAs displayed vital regulatory roles on target genes, which was necessary involved in the complex disease. We therefore examined the expression levels of miRNAs and genes to identify robust signatures for survival benefit analyses. First, we reconstructed subpathway graphs by embedding miRNA components that were derived from low-throughput miRNA-gene interactions. Then, we randomly divided the data sets from The Cancer Genome Atlas (TCGA) into training and testing sets, and further formed 100 subsets based on the training set. Using each subset, we identified survival-related miRNAs and genes, and identified survival subpathways based on the reconstructed subpathway graphs. After statistical analyses of these survival subpathways, the most robust subpathways with the top three ranks were identified, and risk scores were calculated based on these robust subpathways for AML patient prognoses. Among these robust subpathways, three representative subpathways, path: 05200_10 from Pathways in cancer, path: 04110_20 from Cell cycle, and path: 04510_8 from Focal adhesion, were significantly associated with patient survival in the TCGA training and testing sets based on subpathway risk scores. In conclusion, we performed integrated analyses of miRNAs and genes to identify robust prognostic subpathways, and calculated subpathway risk scores to characterize AML patient survival.

Submit a Comment

Your email address will not be published. Required fields are marked *

13 + 9 =

[ HIDE/SHOW ]